|Table of Contents|

Research progress of CAR-T in triple-negative breast cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 24
Page:
4626-4629
Research Field:
Publishing date:

Info

Title:
Research progress of CAR-T in triple-negative breast cancer
Author(s):
LIN Wei; ZHU Jingjing; WANG Jianxun
School of Life Sciences，Beijing University of Chinese Medicine，Beijing 102400，China.
Keywords:
chimeric antigen receptor T cell; triple-negative breast cancer; breast cancer; immunotherapy
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2023.24.028
Abstract:
After decades of development,immunotherapy has achieved encouraging results in tumor treatment.Chimeric antigen receptor T cell (CAR-T) immunotherapy is a kind of adoptive immunotherapy,which has achieved remarkable results in the treatment of hematological malignancies.In solid tumors,CAR-T therapy still has problems to be solved,but it also has great potential to be developed.This article reviews the research progress of CAR-T in triple-negative breast cancer (TNBC).

References:

[1]SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
[2]XIE Y,HU Y,ZHOU N,et al.CAR T-cell therapy for triple-negative breast cancer:Where we are［J］.Cancer Letters,2020,491:121-131.
[3]STAGG J,ALLARD B.Immunotherapeutic approaches in triple-negative breast cancer:latest research and clinical prospects［J］.Therapeutic Advances in Medical Oncology,2013,5(3):169-181.
[4]ZAGAMI P,CAREY LA.Triple negative breast cancer:Pitfalls and progress［J］.NPJ Breast Cancer,2022,8(1):95.
[5]GRADISHAR WJ,ANDERSON BO,ABRAHAM J,et al.Breast cancer,version 3.2020,NCCN clinical practice guidelines in oncology［J］.J Natl Compr Canc Netw,2020,18(4):452-478.
[6]BARTSCH R.ASCO 2020:highlights in breast cancer［J］.Memo,2021,14(1):58-61.
[7]LEE KL,KUO YC,HO YS,et al.Triple-negative breast cancer:current understanding and future therapeutic breakthrough targeting cancer stemness［J］.Cancers (Basel),2019,11(9):1334.
[8]HOADLEY KA,WEIGMAN VJ,FAN C,et al.EGFR associated expression profiles vary with breast tumor subtype［J］.BMC Genomics,2007,8:258.
[9]MONTANO N,CENCI T,MARTINI M,et al.Expression of EGFRvIII in glioblastoma:prognostic significance revisited［J］.Neoplasia,2011,13(12):1113-1121.
[10]XIA L,ZHENG ZZ,LIU JY,et al.Targeting triple-negative breast cancer with combination therapy of EGFR CAR T cells and CDK7 inhibition［J］.Cancer Immunol Research,2021,9(6):707-722.
[11]YANG PX,CAO XJ,CAI HL,et al.The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth［J］.Cellular Immunology,2021,360:104262.
[12]HILLIARD TS.The impact of mesothelin in the ovarian cancer tumor microenvironment［J］.Cancers (Basel),2018,10(9):277.
[13]YANG PX,CAO XJ,CAI HL,et al.The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth［J］.Cellular Immunology,2021,360:104262.
[14]ZAGOURI F,BAGO-HORVATH Z,RSSLER F,et al.High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer［J］.British Journal of Cancer,2013,108(5):1100-1105.
[15]TCHOU J,ZHAO Y,LEVINE BL,et al.Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer［J］.Cancer Immunol Research,2017,5(12):1152-1161.
[16]SIU MKY,KONG DSH,CHAN HY,et al.Paradoxical impact of two folate receptors,FRα and RFC,in ovarian cancer:effect on cell proliferation,invasion and clinical outcome［J］.PLoS One,2012,7(11):e47201.
[17]FURUUCHI K,RYBINSKI K,FULMER J,et al.Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models［J］.Cancer Science,2021,112(6):2467-2480.
[18]YE XS,DENG XN,WEN JY,et al.Folate receptor-alpha targeted 7x19 CAR-γδT suppressed triple-negative breast cancer xenograft model in mice［J］.Journal of Oncology,2022,2022:2112898.
[19]ZHENG Y,FANG YC,LI J.PD-L1 expression levels on tumor cells affect their immunosuppressive activity［J］.Oncology Letters,2019,18(5):5399-5407.
[20]LOTFINEJAD P,KAZEMI T,MOKHTARZADEH A,et al.PD-1/PD-L1 axis importance and tumor microenvironment immune cells［J］.Life Sci,2020,259:118297.
[21]ZHANG J,ZHANG G,ZHANG W,et al.Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancer［J］.Cell Death Differ,2022,29(11):2247-2261.
[22]HARRASSER M,GOHIL SH,LAU H,et al.Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC［J］.Breast Cancer Res,2022,24(1):39.
[23]BEJARANO L,JORDO MJC,JOYCE JA.Therapeutic targeting of the tumor microenvironment［J］.Cancer Discov,2021,11(4):933-959.
[24]YU T,DI G.Role of tumor microenvironment in triple-negative breast cancer and its prognostic significance［J］.Chin J Cancer Res,2017,29(3):237-252.
[25]STBER T,MONJEZI R,WALLSTABE L,et al.Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer［J］.J Immunother Cancer,2020,8(1):e000676.
[26]YAMASHITA N,LONG M,FUSHIMI A,et al.MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer［J］.J Immunother Cancer,2021,9(1):e002115.

Memo

Memo:
高层次人才科研启动经费项目（编号：90011451310032）
Last Update: 1900-01-01